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Background and Aims: Recent experimental models of liver fibrosis
highlighted the importance of liver-infiltrating macrophages for
perpetuating hepatic inflammation by releasing proinflammatory
cytokines and activating hepatic stellate cells (HSC). Monocyte/
macrophage infiltration into the liver was found to be critically
regulated via the chemokine receptor CCR2. In this study,
we investigated the pharmacological inhibition of monocyte
chemoattractant protein-1 (MCP-1, CCL2), the major CCR2 ligand,
using a specific MCP-1 antagonist in two models of murine liver
fibrosis in vivo.
Methods: Liver fibrosis was induced in C57BL/6 wild-type mice
by intraperitoneal injections of carbon tetrachloride (CCl4) twice
weekly over 6 weeks or by feeding a methionine-choline-deficient
diet (MCD) over 8 weeks. Mice received anti-MCP-1 (3×/week, s.c.)
or a non-specific control drug during liver injury models. CCR2-
deficient mice served as controls. The infiltration of immune cells
into the liver was assessed by FACS and immunohistochemistry. The
intrahepatic cytokine profile was analyzed by ELISA. Fibrosis and
fatty degeneration were analyzed by histology (H&E, Sirius Red, oil
red O staining), hydroxyproline content, intrahepatic trigylcerides
and mRNA expression of fibrosis-related genes.
Results: Antagonizing MCP-1 inhibited murine monocyte
chemotaxis in vitro (Boyden chambers). Upon CCl4- or MCD-
induced liver injury in vivo, the infiltration of macrophages into
the liver was significantly decreased in anti-MCP-1 treated mice
(by FACS and immunohistological staining; p < 0.01). In line with
the lower level of intrahepatic macrophages, pro-inflammatory,
anti-inflammatory and profibrogenic cytokines (TNFa, MCP-1, IFNg,
IL-10, IL-6; all p < 0.05) and fibrosis related genes (MCP-1, TNFa,
TGFb, alpha-sma; all p < 0.01) were significantly regulated. In
MCD challenged mice a lower level of fatty liver degeneration
was detected (oil red O staining, intrahepatic triglyceride
measurement, p < 0.05) in anti-MCP-1-treated animals. However,
overall fibrosis development was not significantly altered by anti-
MCP-1 treatment.
Conclusion: These results demonstrate the successful pharma-
cological inhibition of hepatic monocyte/macrophage infiltration
by blocking MCP-1 during liver damage in vivo. The associated
decreased fatty degeneration suggests that inhibition of MCP-1 may
be an interesting novel approach for pharmacological treatment in
liver inflammation and steatohepatitis.
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Background and Aims: Myofibroblast like cells (MFs) can originate
from activated hepatic stellate cells (HSC/MFs), portal fibroblasts
and bone marrow-derived mesenchymal stem cells (MSCs). A
critical pro-fibrogenic feature of MFs is represented by their
ability to migrate towards the site of injury and to align with
nascent and established fibrotic septa in response to several
polypeptides, hypoxia or reactive oxygen species (ROS). Along these
lines, oncostatin M (OSM), a cytokine expressed in cirrhotic liver
and belonging to the interleukin-6 family, has been reported to
orchestrate hypoxia-modulated processes in the liver (development,
regeneration, angiogenesis) involving HIF-1 and to be potentially
involved in the progression of chronic liver diseases (CLDs). In this
study we investigated signaling mechanisms regulating migration
of human HSC/MFs and human, MF-like and bone marrow-derived,
MSCs in response to oncostatin M.
Methods: Signal transduction was evaluated by integrating cell and
molecular biology techniques, whereas non-oriented migration and
chemotaxis were assessed by wound healing assay and the modified
Boyden’s chambers assay, respectively. Morphological analysis was
performed by immunohistochemistry (IHC) on liver specimens from
HCV cirrhotic patients (Metavir F4).
Results: Exposure of pro-fibrogenic cell types to human
recombinant OSM resulted in increased non-oriented migration
and chemotaxis. Moreover, IHC revealed positive stain for OSM
in hepatocytes of cirrhotic nodules, mainly in the proximity of
fibrotic septa. The following features, common to both HSC/MFs
and MSCs were demonstrated by employing specific experimental
approaches:
a. early intracellular ROS generation and activation of Ras/Erk
JNK1/2 as well as of STAT1 and STAT3 signaling pathways and
involvement of hypoxia-inducible factor-1a (HIF-1a);
b. OSM-dependent migration, which was significantly inhibited by
apocynin, indicating NADPH-oxidase as a major source of ROS;
c. OSM-dependent motogenic action that, similarly to hypoxia,
appeared to be exerted in HSC/MFs and MSCs through a biphasic
mechanism requiring early generation of ROS and late HIF1-
dependent expression and release of VEGF.
Conclusions: OSM, which is expressed by hepatocytes in cirrhotic
parenchyma, may contribute to fibrogenesis by stimulating
directional migration of profibrogenic human hepatic MFs through
a biphasic, redox- and HIF-1a/VEGF-dependent mechanism.
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Background: Liver cirrhosis represents the pathological response
of the liver to all forms of chronic injuries and may lead to
hepatocellular carcinoma. Recent evidence have shown that kinase
inhibitors are able to interfere with liver cancer development
and spreading by inhibiting angiogenesis. Angiogenesis is a key
mechanism in both cancer and fibrosis development. Although
sorafenib treatment has been shown to reduce liver fibrosis in
vitro and in vivo, the role of this molecule in interfering with the
mechanisms of fibrogenesis are still under investigation.
Aim: To investigate the role of sorafenib, a multikinase inhibitor, in
a mouse model of liver fibrogenesis.
Methods: Wild-type mice were treated by i.p. injection of CCl4
(0.2ml/kg three times a week) for five weeks to induce fibrosis.
Mice received orally either sorafenib (at the dose of 50mg/kg
of body-weight) or vehicle starting 1 week later than fibrosis-
induction.
Results: Liver fibrosis induced by CCL4 was significantly reduced
by sorafenib administration. Morphometry after Sirius red staining
showed reduced collagen deposition in CCL4-treated mice exposed
to sorafenib, in comparison to control mice treated with CCL4 and
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